Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Pseudomonas Aeruginosa Infection

Drug Information

Target Indication

Pseudomonas Aeruginosa Infection

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

INSM

Insmed Incorporated

Related Pipeline

Pulmonary Hypertension

NTM Lung Infection Due to MAC

Cystic Fibrosis

Non-Cystic Fibrosis Bronchiectasis

Pulmonary Hypertension

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts